Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral drug
Biotech
Gilead cancels HIV trial as clinical hold remains intact
After discussions with the FDA, Gilead is discontinuing the Wonders-2 trial comparing the combo of GS-1720 and GS-4182 to Biktarvy.
Darren Incorvaia
Apr 1, 2026 4:50pm
Study finds HIV can evolve to resist lenacapavir—at a cost
Jan 7, 2026 2:00pm
As measles surges, the first treatment remains a pipe dream
Jul 17, 2025 2:02pm
Enanta's RSV antiviral crushes viral load in challenge study
Sep 26, 2024 7:43am
Protease inhibitor outperforms Paxlovid protecting lungs of mice
Mar 14, 2024 6:30am
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
Nov 21, 2023 8:30am
